Clenbuterol 20mcg/tab 50 Tabletten by Sopharma

Usage

1. Establish your true maintenance calorie intake using a two-week dietary tracking baseline before introducing clenbuterol — recomposition outcomes depend on caloric accuracy, not guesswork.
2. Set dietary protein at a minimum of 2.2 g/kg bodyweight daily from whole food sources and/or whey protein; this is the structural substrate that the concurrent anabolic signal will utilise.
3. Begin with one 20 mcg Sopharma tablet taken before 9 a.m. on an empty or light stomach; morning administration aligns the adrenergic peak with your highest-activity portion of the day.
4. Advance the dose by one tablet (20 mcg) every three to four days only if resting morning heart rate, measured before rising, remains within 15 bpm of your pre-cycle personal baseline.
5. Combine with a moderate anabolic base — testosterone enanthate 300–400 mg/week or equivalent — to supply androgen receptor occupancy that drives muscle protein synthesis while clenbuterol handles lipolytic pressure.
6. Log each blister cavity removed as your daily compliance record; after six to eight weeks, discontinue and allow a minimum fourteen-day agonist-free recovery interval before assessing whether a second recomp block is warranted.

Warnings

Frequently asked questions

Can clenbuterol genuinely support simultaneous fat loss and muscle gain, or is that just marketing?

Simultaneous fat loss and muscle gain — true recomposition — is achievable under specific conditions: near-maintenance calories, high protein intake, consistent resistance training, and an adrenergic agent like clenbuterol to elevate fatty acid mobilisation beyond what diet alone produces. Clenbuterol raises lipolytic rate without the severe caloric deficit that would otherwise suppress anabolic hormones, making parallel adaptations physiologically realistic rather than purely theoretical.

What calorie intake strategy works best when using clenbuterol for a recomp goal?

Maintenance calories — or a very small surplus of 100–150 kcal — typically outperform aggressive deficits for recomposition. At this intake level, clenbuterol's adrenergic stimulation creates the lipolytic pressure without the leptin suppression and cortisol elevation that accompany deep cuts. Protein should sit at or above 2.2 g/kg bodyweight daily to maximise muscle protein synthesis rates while the fat-loss stimulus operates in parallel.

Which anabolic compounds pair most effectively with clenbuterol in a recomposition cycle?

Testosterone enanthate at moderate doses (300–400 mg/week) or boldenone undecylenate are frequently cited as recomp anchors because both sustain androgen receptor occupancy and elevate red blood cell count without excessive water retention that would obscure the fat-loss outcome. These androgens supply the anabolic signal that builds and protects lean tissue while clenbuterol addresses the lipolytic side of the recomp equation concurrently.

How do I split Sopharma's 20 mcg tablets across the day during a recomp protocol?

The 50-tablet blister pack uses individual cavity perforation, making it straightforward to track daily intake. For a recomp dose of 40–60 mcg daily, two to three tablets taken in the early morning — before 9 a.m. — minimises adrenergic interference with sleep while maintaining plasma levels through peak training hours. Each tablet should be swallowed whole with water; splitting the 20 mcg tablet is not recommended due to the low active load per unit.

How long does a body recomposition phase with Sopharma Clenbuterol typically run before a break is needed?

A well-structured recomp phase using clenbuterol typically runs six to eight weeks before beta-2 receptor sensitivity declines meaningfully. The 50-tablet pack at 40–80 mcg daily covers this window precisely. Following the active phase, a minimum two-week agonist-free interval allows receptor density to recover, at which point a second recomp block — or a transition to a defined cut — can begin with restored adrenergic responsiveness. (2) angle_used

Manufacturer

Sopharma AD is a Bulgarian pharmaceutical company headquartered in Sofia, operating one of Central and Eastern Europe's largest licensed drug manufacturing sites. The facility holds EU GMP certification and produces finished dosage forms — including low-dose oral tablets such as Clenbuterol 20 mcg — under validated manufacturing processes that encompass API weighing, blending, compression, and blister sealing within environmentally controlled production suites. Finished-tablet HPLC potency assay and LAL endotoxin testing are standard release requirements applied to every production batch, ensuring that the declared 20 mcg active content is confirmed at the discrete tablet level before distribution. Sopharma's manufacturing capacity spans human pharmaceuticals, veterinary products, and nutraceutical formulations, giving it cross-category technical depth that underpins the precision demanded by sub-milligram-range oral tablet production.